New White Paper: The Microbiome and Immuno-Oncology
As science explores the effects of the microbiome on the immune system and its role in treating cancer, drug developers are investing substantially to capitalize on findings connecting the microbiome, immunology, and oncology. For our latest white paper, Back Bay Life Science Advisors analyzed the activity of drug developers looking to harness microbial pathways to improve cancer treatment, the current drug pipeline, active clinical trials, and evolving regulatory and IP issues for the development of these technologies.